|  |  | 

India Top Headlines

Covaxin Phase 3 Trials Show Interim Clinical Efficacy of 78% | India News


NEW DELHI: Bharat Biotech’s Covaxin vaccine has shown an interim 78% efficacy against coronavirus, based on the results of phase 3 trials.
The vaccine has also been shown to be 100% effective against severe Covid-19.
Covaxin had previously shown 81% efficacy in preventing Covid-19 after the second dose, based on interim results of phase III trials released by its developer Bharat Biotech.
The company had said that the first interim analysis is based on 43 cases of Covid-19, of which 36 cases were observed in the group of volunteers who received the placebo compared to 7 cases observed in volunteers who received the two doses of Covaxin. , which resulted in an efficiency of 80.6%.

Original source